Recipients, donors, and CBT characteristics with available CBU samples and according to CTLA4-CBU genotyping (n = 696)
| Recipients . | AA-CBU genotyping, n = 162 . | AG-CBU genotyping, n = 349 . | GG-CBU genotyping, n = 185 . |
|---|---|---|---|
| Male sex, n | 79 | 200 | 110 |
| Age, median (range), y | 17 (0.4-64) | 16 (0.3-67) | 16 (0.6-69) |
| Weight, median (range), kg | 49 (5.5-95) | 50 (6-112) | 52 (6-119) |
| Children ≤18 y, n | 85 | 188 | 102 |
| Positive CMV serology, n | 56 | 125 | 76 |
| Major ABO incompatibility, n | 31 | 99 | 60 |
| Diagnostic, n | |||
| ALL | 63 | 135 | 76 |
| AML | 53 | 123 | 54 |
| MDS | 18 | 32 | 22 |
| CML | 9 | 16 | 9 |
| CLL | 3 | 2 | 0 |
| Lymphoma | 9 | 29 | 17 |
| Myeloma | 0 | 5 | 2 |
| Histiocytosis | 6 | 7 | 5 |
| Others | 1 | 0 | 0 |
| HLA compatibility, n | |||
| 6/6 | 19 | 35 | 14 |
| 5/6 | 59 | 136 | 71 |
| 4/6 | 75 | 155 | 88 |
| 3/6 | 3 | 13 | 6 |
| 2/6 | 2 | 1 | 3 |
| Disease status at time of CBT, n | |||
| Early | 56 | 119 | 50 |
| Intermediate | 58 | 129 | 73 |
| Advanced | 162 | 346 | 182 |
| Conditioning, n | |||
| Myeloablative | 130 | 283 | 143 |
| Nonmyeloablative | 32 | 62 | 38 |
| GVHD prophylaxis, n | |||
| CsA ± others | 143 | 295 | 158 |
| MTX ± others | 10 | 10 | 10 |
| Others | 2 | 7 | 4 |
| Use of ATG and /or monoclonal antibody, n | |||
| Yes | 121 | 281 | 136 |
| No | 34 | 52 | 38 |
| Infused TNC dose, median (range), ×107/kg | 3.5 (0.9-30) | 3.3 (0.6-22) | 3.4 (0.7-21) |
| Infused CD34+ cell dose, median (range), ×105/kg | 1.5 (0.2-20) | 1.5 (0.2-39) | 1.4 (0.3-18) |
| Follow-up (range), mo | 40 (4-181) | 55 (1-160) | 48 (1-195) |
| Recipients . | AA-CBU genotyping, n = 162 . | AG-CBU genotyping, n = 349 . | GG-CBU genotyping, n = 185 . |
|---|---|---|---|
| Male sex, n | 79 | 200 | 110 |
| Age, median (range), y | 17 (0.4-64) | 16 (0.3-67) | 16 (0.6-69) |
| Weight, median (range), kg | 49 (5.5-95) | 50 (6-112) | 52 (6-119) |
| Children ≤18 y, n | 85 | 188 | 102 |
| Positive CMV serology, n | 56 | 125 | 76 |
| Major ABO incompatibility, n | 31 | 99 | 60 |
| Diagnostic, n | |||
| ALL | 63 | 135 | 76 |
| AML | 53 | 123 | 54 |
| MDS | 18 | 32 | 22 |
| CML | 9 | 16 | 9 |
| CLL | 3 | 2 | 0 |
| Lymphoma | 9 | 29 | 17 |
| Myeloma | 0 | 5 | 2 |
| Histiocytosis | 6 | 7 | 5 |
| Others | 1 | 0 | 0 |
| HLA compatibility, n | |||
| 6/6 | 19 | 35 | 14 |
| 5/6 | 59 | 136 | 71 |
| 4/6 | 75 | 155 | 88 |
| 3/6 | 3 | 13 | 6 |
| 2/6 | 2 | 1 | 3 |
| Disease status at time of CBT, n | |||
| Early | 56 | 119 | 50 |
| Intermediate | 58 | 129 | 73 |
| Advanced | 162 | 346 | 182 |
| Conditioning, n | |||
| Myeloablative | 130 | 283 | 143 |
| Nonmyeloablative | 32 | 62 | 38 |
| GVHD prophylaxis, n | |||
| CsA ± others | 143 | 295 | 158 |
| MTX ± others | 10 | 10 | 10 |
| Others | 2 | 7 | 4 |
| Use of ATG and /or monoclonal antibody, n | |||
| Yes | 121 | 281 | 136 |
| No | 34 | 52 | 38 |
| Infused TNC dose, median (range), ×107/kg | 3.5 (0.9-30) | 3.3 (0.6-22) | 3.4 (0.7-21) |
| Infused CD34+ cell dose, median (range), ×105/kg | 1.5 (0.2-20) | 1.5 (0.2-39) | 1.4 (0.3-18) |
| Follow-up (range), mo | 40 (4-181) | 55 (1-160) | 48 (1-195) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CsA, cyclosporin A; MDS, myelodysplastic syndrome; MTX, methotrexate.